BR112022001336A8 - Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo - Google Patents

Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo

Info

Publication number
BR112022001336A8
BR112022001336A8 BR112022001336A BR112022001336A BR112022001336A8 BR 112022001336 A8 BR112022001336 A8 BR 112022001336A8 BR 112022001336 A BR112022001336 A BR 112022001336A BR 112022001336 A BR112022001336 A BR 112022001336A BR 112022001336 A8 BR112022001336 A8 BR 112022001336A8
Authority
BR
Brazil
Prior art keywords
her2
antibody
bispecific
bispecific anti
cancer
Prior art date
Application number
BR112022001336A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112022001336A2 (pt
Inventor
Chung Hyejin
Yong Yeryoung
Park Kyeongsu
Park Eunyoung
Jung Ui-Jung
Lee Yangsoon
Kim Eunjung
Son Yong-Gyu
Son Wonjun
Ahn Seawon
Yeom Donghoon
Lee Chanmoo
Hong Junghyeon
Young Song Moo
Lee Eun-Jung
Bong Park Young
Rae Lee Na
Kim Taewang
Original Assignee
Abl Bio Inc
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc, Yuhan Corp filed Critical Abl Bio Inc
Publication of BR112022001336A2 publication Critical patent/BR112022001336A2/pt
Publication of BR112022001336A8 publication Critical patent/BR112022001336A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022001336A 2019-07-26 2020-07-27 Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo BR112022001336A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878951P 2019-07-26 2019-07-26
US202063024608P 2020-05-14 2020-05-14
PCT/KR2020/009871 WO2021020846A1 (en) 2019-07-26 2020-07-27 Anti-her2/anti-4-1bb bispecific antibody and use thereof

Publications (2)

Publication Number Publication Date
BR112022001336A2 BR112022001336A2 (pt) 2022-03-22
BR112022001336A8 true BR112022001336A8 (pt) 2023-02-07

Family

ID=74190718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001336A BR112022001336A8 (pt) 2019-07-26 2020-07-27 Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo

Country Status (11)

Country Link
US (2) US12240913B2 (https=)
EP (1) EP4004054A4 (https=)
JP (2) JP7725446B2 (https=)
KR (2) KR102820082B1 (https=)
CN (2) CN118638240A (https=)
AU (1) AU2020320233A1 (https=)
BR (1) BR112022001336A8 (https=)
CA (1) CA3147423A1 (https=)
MX (1) MX2022001022A (https=)
WO (1) WO2021020846A1 (https=)
ZA (1) ZA202200906B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211147A1 (es) 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
CA3169910A1 (en) * 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
EP4281467A4 (en) * 2021-01-25 2024-12-04 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
MX2024005999A (es) * 2021-11-19 2024-05-30 Ap Biosciences Inc Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer.
JP2025512915A (ja) * 2022-04-07 2025-04-22 ユハン コーポレーション Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物
KR20250148463A (ko) * 2024-04-03 2025-10-14 주식회사유한양행 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CA2984624A1 (en) 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
KR20170138574A (ko) 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
CN108064246A (zh) * 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
FI3436048T3 (fi) * 2016-03-31 2025-09-15 Biontech Us Inc Neoantigeeneja ja niiden käyttömenetelmiä
AU2017252233A1 (en) * 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
AU2017355544A1 (en) * 2016-11-03 2019-05-16 Juno Therapeutics, Inc. Combination therapy of a T cell therapy and a BTK inhibitor
IL268836B2 (en) * 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11202000503QA (en) * 2017-07-20 2020-02-27 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途

Also Published As

Publication number Publication date
KR102820082B1 (ko) 2025-06-13
EP4004054A4 (en) 2023-10-25
US20250163180A1 (en) 2025-05-22
US20210024650A1 (en) 2021-01-28
CN114206941B (zh) 2024-07-02
JP7725446B2 (ja) 2025-08-19
WO2021020846A1 (en) 2021-02-04
CN118638240A (zh) 2024-09-13
KR20220038768A (ko) 2022-03-29
MX2022001022A (es) 2022-04-18
US12240913B2 (en) 2025-03-04
AU2020320233A1 (en) 2022-02-17
AU2020320233A8 (en) 2022-02-24
CA3147423A1 (en) 2021-02-04
JP2025179060A (ja) 2025-12-09
CN114206941A (zh) 2022-03-18
BR112022001336A2 (pt) 2022-03-22
ZA202200906B (en) 2023-11-29
JP2022542574A (ja) 2022-10-05
KR20250090381A (ko) 2025-06-19
EP4004054A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
BR112022001329A2 (pt) Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
SA522432225B1 (ar) Cdk2 أمينات ثنائية الحلقة كمثبطات
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CL2019001740A1 (es) Novedoso conjugado de amanitina.
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
EA201892587A1 (ru) Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака
CL2018003407A1 (es) Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
MX2021006731A (es) Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
ZA202309150B (en) Antibody against nkp46 and application of antibody
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors
MX2019010060A (es) Composiciones y metodo para tratar cancer.
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
BR112021019448A2 (pt) Métodos para o tratamento de beta-talassemia
SA522432781B1 (ar) مركب مضاد pd-l1

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YUHAN CORPORATION (KR)